Everipedia Logo
Everipedia is now IQ.wiki - Join the IQ Brainlist and our Discord for early access to editing on the new platform and to participate in the beta testing.
U-47700

U-47700

Physical Sample of U-47700

Physical Sample of U-47700[5]

U-47700 is an opioid analgesic drug developed by a team at Upjohn in the 1970s[1] which has around 7.5 times the potency of morphine in animal models.[2][3][4]

U-47700 is a structural isomer of the earlier opioid AH-7921[6] and the result of a great deal of work elucidating the quantitative structure–activity relationship of the scaffold. Upjohn looked for the key moieties which gave the greatest activity[7] and posted over a dozen patents on related compounds, each optimizing one moiety[8][9][10][11][12][13][14][15] until they discovered that U-47700 was the most active.[16]

U-47700 became the lead compound of selective kappa-opioid receptor ligands such as U-50488, U-51754 (containing a single methylene spacer difference) and U-69,593, which share very similar structures.[17][18] Although not used medically, the selective kappa ligands are used in research.[19][20]

U-47700
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class A
  • US: Schedule I
  • Illegal in Finland, Sweden
Identifiers
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H22Cl2N2O
Molar mass329.27 g·mol−1
3D model (JSmol)
  • Interactive image [61]
☒N☑Y(what is this?)(verify) [62]

Side effects

U-47700 has never been studied on humans, but would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching and respiratory depression which could be harmful or fatal.[21][22][23][24][25][26][27][28] Tachycardia was another side effect encountered with U-47700 use.[28] Tolerance and dependence would be expected to develop.[29]

Deaths

Combined consumption of U-47700 with fentanyl and flubromazepam caused one fatality in Belgium and Germany, respectively.[30][31][32] One death was reported in Ireland,[33] another one in Italy.[34] 17 opioid overdoses and several deaths in the United States had initially been associated with U-47700 in April 2016,[35] as of September 2016 at least 15 fatalities were confirmed. By December 2017, at least 46 fatalities had been associated with the use of U-47700. [36][37][38][39][40][41][42]

U-47700 was found in combination with fentanyl during the autopsy of the American guitarist Prince in 2016.[43]

Detection in biological fluids

U-47700 may be measured in serum, plasma, blood or urine to monitor for abuse, confirm a diagnosis of poisoning, or assist in a medicolegal death investigation. Serum or blood U-47700 concentrations are expected to be in a range of 10–250 μg/L in intoxicated patients and 100-1500 μg/L in deceased victims of acute overdosage. The analysis usually involves liquid chromatography-mass spectrometry.[44]

Following its sale as a designer drug, U-47700 was made illegal in Sweden on January 26, 2016.[45]

U-47700 was emergency scheduled in Ohio on May 3, 2016 by executive order of Governor John Kasich.[46]

U-47700 was emergency scheduled in Florida on September 27, 2016 by an emergency rule of Florida Attorney General Pam Bondi.[47]

Responding to a perceived threat to public health and safety, the U.S. Drug Enforcement Administration has placed U-47700 into Schedule 1 of the Controlled Substances Act, effective November 14, 2016.[48]

U-47700 was placed into Schedule 1 of South Dakota's Controlled Substance Schedule. It was signed by Governor Daugaard on February 9, 2017.[49]

See also

  • Metonitazene

  • Spiradoline

  • U-69,593

  • U-77891

References

[1]
Citation Linkpatents.google.comJacob Szmuszkovicz (4 July 1978). "Patent US4098904 - Analgesic N-(2-aminocycloaliphatic)benzamides".
Sep 29, 2019, 8:16 AM
[2]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/2999404Cheney BV, Szmuszkovicz J, Lahti RA, Zichi DA (December 1985). "Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor". Journal of Medicinal Chemistry. 28 (12): 1853–64. doi:10.1021/jm00150a017. PMID 2999404.
Sep 29, 2019, 8:16 AM
[3]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/4416926Harper NJ, Veitch GB, Wibberley DG (November 1974). "1-(3,4-Dichlorobenzamidomethyl)cyclohexyldimethylamine and related compounds as potential analgesics". Journal of Medicinal Chemistry. 17 (11): 1188–93. doi:10.1021/jm00257a012. PMID 4416926.
Sep 29, 2019, 8:16 AM
[4]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/6128415Szmuszkovicz J, Von Voigtlander PF (October 1982). "Benzeneacetamide amines: structurally novel non-m mu opioids". Journal of Medicinal Chemistry. 25 (10): 1125–6. doi:10.1021/jm00352a005. PMID 6128415.
Sep 29, 2019, 8:16 AM
[5]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/29282436Alzghari SK, Fleming SW, Rambaran KA, Long JE, Burkhart S, An J, Furmaga J (October 2017). "U-47700: An Emerging Threat". Cureus. 9 (10): e1791. doi:10.7759/cureus.1791. PMC 5741271. PMID 29282436.
Sep 29, 2019, 8:16 AM
[6]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/4207044Brittain RT, Kellett DN, Neat ML, Stables R (September 1973). "Proceedings: Anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides". British Journal of Pharmacology. 49 (1): 158P–159P. doi:10.1111/j.1476-5381.1973.tb08279.x. PMC 1776456. PMID 4207044.
Sep 29, 2019, 8:16 AM
[7]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/2687936Michalson ET, Szmuszkovicz J (1989). Medicinal agents incorporating the 1,2-diamine functionality. Progress in Drug Research. 33. Birkhäuser Basel. pp. 135–149. doi:10.1007/978-3-0348-9146-2_6. ISBN 9783034891462. PMID 2687936.
Sep 29, 2019, 8:16 AM
[8]
Citation Linkpatents.google.comMullins DD (28 June 1966). "Patent US US3258489 - N-(1-aminocyclohexylmethyl)anilines and N-(1-nitrocyclohexylmethyl)anilines".
Sep 29, 2019, 8:16 AM
[9]
Citation Linkpatents.google.comHarper NJ, Veitch GB (17 August 1976). "Patent US3975443 - 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine".
Sep 29, 2019, 8:16 AM
[10]
Citation Linkpatents.google.comJacob Szmuszkovicz Kalamazoo (3 March 1970). "Patent US3499033 - Ethers of α-phenyl-2-aminocycloalkanemethanols".
Sep 29, 2019, 8:16 AM
[11]
Citation Linkpatents.google.comJacob Szmuszkovicz (5 May 1970). "Patent US3510492 - 2-anilino and 2-anilinomethyl cycloalkylamines".
Sep 29, 2019, 8:16 AM
[12]
Citation Linkpatents.google.comRynbrandt RH, Skaletzky LL (7 March 1972). "Patent US3647804 - Cycloalkanecarboxamides".
Sep 29, 2019, 8:16 AM
[13]
Citation Linkpatents.google.comRoll W (23 July 1974). "Patent US3825595 - N-cyclopentyl-N-2-hydroxyalkyl-ring-substituted benzamides".
Sep 29, 2019, 8:16 AM
[14]
Citation Linkpatents.google.comHarper NJ, Veitch GB (20 September 1977). "Patent US4049663 - Ethylene diamine derivatives".
Sep 29, 2019, 8:16 AM
[15]
Citation Linkpatents.google.comCollins RJ, Kaplan LJ, Ludens JH, Von Voigtlander PF (9 April 1982). "Patent US4463013 - Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs".
Sep 29, 2019, 8:16 AM
[16]
Citation Link//doi.org/10.1007%2F978-1-4899-0585-7_11Casy AF, Parfitt RT (1986). Miscellaneous Groups of Analgesics. Opioid Analgesics. Springer US. pp. 385–403. doi:10.1007/978-1-4899-0585-7_11. ISBN 9781489905857.
Sep 29, 2019, 8:16 AM
[17]
Citation Link//doi.org/10.3987%2Fcom-99-s27Szmuszkovicz J, Zhao S, Totleben MJ, Mizsak SA, Freeman JP (2000). "Phenanthridone Analogs of the Opiate Agonist U-47,700 in the trans-1,2-Diaminocyclohexane Benzamide Series". Heterocycles. 52 (1): 325–332. doi:10.3987/com-99-s27.
Sep 29, 2019, 8:16 AM
[18]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/2855852Loew G, Lawson J, Toll L, Frenking G, Berzetei-Gurske I, Polgar W (1988). "Structure activity studies of two classes of beta-amino-amides: the search for kappa-selective opioids" (PDF). NIDA Research Monograph. 90: 144–51. PMID 2855852.
Sep 29, 2019, 8:16 AM
[19]
Citation Link//doi.org/10.1007%2F978-3-0348-8730-4_4Szmuszkovicz, Jacob (1999). U-50,488 and the к receptor: A personalized account covering the period 1973 to 1990. Progress in Drug Research. Birkhäuser Basel. pp. 167–195. doi:10.1007/978-3-0348-8730-4_4. ISBN 9783034887304.
Sep 29, 2019, 8:16 AM
[20]
Citation Link//www.ncbi.nlm.nih.gov/pubmed/26519268Tsibulnikov SY, Maslov LN, Mukhomedzyanov AV, Krylatov AV, Tsibulnikova MR, Lishmanov YB (October 2015). "Prospects of Using of κ-Opioid Receptor Agonists U-50,488 and ICI 199,441 for Improving Heart Resistance to Ischemia/Reperfusion". Bulletin of Experimental Biology and Medicine. 159 (6): 718–21. doi:10.1007/s10517-015-3057-8. PMID 26519268.
Sep 29, 2019, 8:16 AM